IS8498A - Notkun katepsín K tálma til að meðhöndla alvarlega beintapssjúkdóma - Google Patents

Notkun katepsín K tálma til að meðhöndla alvarlega beintapssjúkdóma

Info

Publication number
IS8498A
IS8498A IS8498A IS8498A IS8498A IS 8498 A IS8498 A IS 8498A IS 8498 A IS8498 A IS 8498A IS 8498 A IS8498 A IS 8498A IS 8498 A IS8498 A IS 8498A
Authority
IS
Iceland
Prior art keywords
cathepsin
inhibitors
treatment
bone loss
severe bone
Prior art date
Application number
IS8498A
Other languages
English (en)
Inventor
Missbach Martin
Gamse Rainer
Trechsel Ulrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IS8498A publication Critical patent/IS8498A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS8498A 2003-11-19 2006-06-06 Notkun katepsín K tálma til að meðhöndla alvarlega beintapssjúkdóma IS8498A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03026430 2003-11-19
PCT/EP2004/004155 WO2005049028A1 (en) 2003-11-19 2004-04-19 Use of cathepsin k inhibitors in severe bone loss diseases

Publications (1)

Publication Number Publication Date
IS8498A true IS8498A (is) 2006-06-06

Family

ID=34610055

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8498A IS8498A (is) 2003-11-19 2006-06-06 Notkun katepsín K tálma til að meðhöndla alvarlega beintapssjúkdóma

Country Status (16)

Country Link
US (1) US20070135448A1 (is)
EP (1) EP1686995A1 (is)
JP (1) JP2007511548A (is)
KR (1) KR20060107792A (is)
CN (1) CN1882343A (is)
AU (1) AU2004290874A1 (is)
BR (1) BRPI0416755A (is)
CA (1) CA2545723A1 (is)
IL (1) IL175436A0 (is)
IS (1) IS8498A (is)
MA (1) MA28174A1 (is)
MX (1) MXPA06005635A (is)
NO (1) NO20062870L (is)
TN (1) TNSN06147A1 (is)
TW (1) TW200526198A (is)
WO (1) WO2005049028A1 (is)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US20080076723A1 (en) * 2006-09-27 2008-03-27 Sylvan Pharmaceuticals Pty Ltd. Inhibition of cathepsin K activity and the treatment and prevention of disease
CA2678717A1 (en) * 2007-02-28 2008-09-04 Sanofi-Aventis Imaging probes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1273444C (zh) * 1997-11-05 2006-09-06 诺瓦提斯公司 二肽腈
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
JP3892187B2 (ja) * 1998-11-12 2007-03-14 生化学工業株式会社 環状アミド誘導体
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
PE20050328A1 (es) * 2003-07-21 2005-06-16 Novartis Ag Combinaciones de un bisfosfonato y un inhibidor de catepsina k

Also Published As

Publication number Publication date
WO2005049028A1 (en) 2005-06-02
KR20060107792A (ko) 2006-10-16
EP1686995A1 (en) 2006-08-09
JP2007511548A (ja) 2007-05-10
CA2545723A1 (en) 2005-06-02
AU2004290874A1 (en) 2005-06-02
MXPA06005635A (es) 2006-08-17
BRPI0416755A (pt) 2007-02-27
TNSN06147A1 (en) 2007-11-15
IL175436A0 (en) 2008-04-13
MA28174A1 (fr) 2006-09-01
US20070135448A1 (en) 2007-06-14
NO20062870L (no) 2006-08-18
CN1882343A (zh) 2006-12-20
TW200526198A (en) 2005-08-16

Similar Documents

Publication Publication Date Title
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
PL374700A1 (en) Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
NO20035156L (no) Fremgangsmåter for brønnbehandling
EP1643986A4 (en) PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
SI1531819T1 (sl) Uporaba IxB-kinaznih inhibitorjev pri terapiji bolečin
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
ITMI20031311A0 (it) Formulazioni per il trattamento di disturbi artrosici
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
IL175412A0 (en) Use of specific histones for the treatment of parasitic diseases
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
IS8498A (is) Notkun katepsín K tálma til að meðhöndla alvarlega beintapssjúkdóma
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
EP1658274A4 (en) INHIBITORS OF CATHEPSIN S
GB2410744B (en) Kinase inhibitors for the treatment of disease
IS8477A (is) Beta-laktöm til að meðhöndla MTK sjúkdóma
EP1677782A4 (en) INHIBITORS OF CATHEPSIN S
DK1646387T3 (da) Anvendelse af indazol-derivater til behandling af neuropatiske smerter
IS8496A (is) Samsetningar til meðhöndlunar á fjölgunarsjúkdómum
ITVE20020040A1 (it) Procedimento di trattamento delle pelli. -